Molecular Drivers and Precision Therapeutics in Oncology

Topic Information

Dear Colleagues,

Monumental discoveries (such as oncogenes, multi-step accumulation of genetic and epigenetic changes in tumorigenesis, and the hallmarks of cancer) and comprehensive analysis of datasets (such as the Cancer Genome Atlas (TCGA), the Human Tumor Atlas Network (HTAN), and the PanCancer Atlas) have paved the way for precision oncology. We are entering an era in which therapeutics based on the understanding of driver genes, oncogenic molecular signatures, tumor imaging patterns, clinical presentations, and theranostic applications will treat cancers in a more targeted and personalized manner.

We invite contributions of cutting-edge research and review articles that report the recent advancements in validating molecular drivers, utilizing software and AI tools in large database analysis, and employing targeted theranostic strategies to advance precision oncology.

Dr. Chien-An Hu
Dr. Kelly Wentz-Hunter
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biophysica biophysica	1.4	2.3	2021	15.7 Days	CHF 1200	Submit
Current Issues in Molecular Biology cimb	3.0	3.7	1999	16.3 Days	CHF 2200	Submit
International Journal of Molecular Sciences ijms	4.9	9.0	2000	17.8 Days	CHF 2900	Submit
International Journal of Translational Medicine ijtm	-	2.2	2021	28.2 Days	CHF 1200	Submit
Lymphatics lymphatics	-	-	2023	26.3 Days	CHF 1000	Submit

Preprints.org is a multidisciplinary platform offering a preprint service designed to facilitate the early sharing of your research. It supports and empowers your research journey from the very beginning.

MDPI Topics is collaborating with Preprints.org and has established a direct connection between MDPI journals and the platform. Authors are encouraged to take advantage of this opportunity by posting their preprints at Preprints.org prior to publication:

1. Share your research immediately: disseminate your ideas prior to publication and establish priority for your work.
2. Safeguard your intellectual contribution: Protect your ideas with a time-stamped preprint that serves as proof of your research timeline.
3. Boost visibility and impact: Increase the reach and influence of your research by making it accessible to a global audience.
4. Gain early feedback: Receive valuable input and insights from peers before submitting to a journal.
5. Ensure broad indexing: Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (1 paper)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All IJMS Biophysica IJTM CIMB Lymphatics

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 2006 KB)

23 pages, 12471 KB  

Open AccessArticle

Elucidating the PTK2-Targeted Anti-Hepatocellular Carcinoma Effects of Euphorbia helioscopia L. via Integrated Network Pharmacology, Mendelian Randomization, and Experimental Validation

by Jianhua Zhu, Li Qian, Chuanjun Yuan, Jia Sun, Jie Pan, Ting Liu, Yang Jin, Yongjun Li, Lin Zheng, Chunhua Liu and Yuan Lu

Curr. Issues Mol. Biol. 2026, 48(2), 213; https://doi.org/10.3390/cimb48020213 - 14 Feb 2026

Viewed by 400

Abstract

Euphorbia helioscopia L. (Zeqi, ZQ) is a traditional Chinese herb used to treat various tumors, but its molecular mechanisms against hepatocellular carcinoma (HCC) remain unclear. This study aims to elucidate the anti-HCC mechanisms of ZQ using chemical profiling, bioinformatics, Mendelian randomization (MR), and [...] Read more.

Euphorbia helioscopia L. (Zeqi, ZQ) is a traditional Chinese herb used to treat various tumors, but its molecular mechanisms against hepatocellular carcinoma (HCC) remain unclear. This study aims to elucidate the anti-HCC mechanisms of ZQ using chemical profiling, bioinformatics, Mendelian randomization (MR), and experimental validation. A total of 104 compounds were identified from ZQ, with 18 targeting HCC-related proteins. Bioinformatics and MR analyses revealed PTK2 as a core target associated with HCC risk. ZQ significantly suppressed H22 tumor growth in male ICR mice and inhibited PTK2/PI3K/AKT phosphorylation. Molecular docking and dynamics simulations confirmed stable binding between key ZQ compounds and PTK2. These results suggest that ZQ exerts anti-HCC effects through PTK2 inhibition and modulation of the PI3K/AKT pathway, supporting its potential as a multi-targeted therapeutic for HCC. Full article

(This article belongs to the Topic Molecular Drivers and Precision Therapeutics in Oncology)

►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-1